To investigate niraparib’s activity in vivo, we evaluated niraparib monotherapy activity in a panel of 10 NSCLC PDX models, six of which contained deleterious biallelic ATM mutations and four with non-ATM, non-BRCA HRR deleterious biallelic mutations. The gene discussed is ATM; the disease is non-small cell lung carcinoma.